title: Thrombosis, leiomyoma and GnRH-a therapy. A case report.
abstract: BACKGROUND
  Diverse complications have been reported in association with the growth and medical treatment of uterine leiomyomata. Infarction and necrosis may be common and incite complications from parasitic vascular attachment, pain and thrombosis. The rarity of severe complications in this situation warrants presentation of the following unique association.
  
  
  METHODS
  A 33-year-old female, gravida 1, para 1, was treated with gonadotropin-releasing hormone agonist (GnRH-a) for three months prior to laparotomy and removal of a solitary, 5,190-g, pedunculated myoma. The mass had secured an additional vascular supply from the transverse colon and omentum. Although the immediate postoperative course was uncomplicated, delayed onset of abdominal pain and fever lead to the diagnosis of superior mesenteric and portal vein thrombosis. Portal vein thrombosis responded to thrombolytic infusion into the superior mesenteric artery. Superior mesenteric vein thrombosis persisted, with evidence of early vascular recanalization. After six weeks of additional anticoagulation, assessment by computed tomographic scan showed complete resolution of all thrombi.
  
  
  CONCLUSIONS
  While thrombosis has been reported with GnRH-a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size. Steroid hormone deprivation potentially contributed to neovascularization and bowel involvement.
authors.affiliation: Department of Obstetrics and Gynecology, University of Florida-Pensacola 32503, USA.
authors.forename: B A
authors.initials: BA
authors.lastname: Ripps
authors.forename: W B
authors.initials: WB
authors.lastname: Nason
authors.forename: T B
authors.initials: TB
authors.lastname: Tan
authors.forename: S W
authors.initials: SW
authors.lastname: Mietling
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy*; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008642:Mesenteric Veins; D011169:Portal Vein; D013927:Thrombosis / Q000139:chemically induced* / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D003692:Delayed-Action Preparations; D016729:Leuprolide